SkinBioTherapeutics, a life science company focused on skin health, has agreed an eight month extension to its research contract with the University of Manchester to June 2018.
The company said that the contract extension includes provision for the appointment of a second technician to the company. This will increase the company’s ability to develop its SkinBiotix platform.
Furthermore, the company announces that it has recently demonstrated activity of SkinBiotix at a range of doses in human skin models, and also completed the design of two human safety trials. If successful, these trials will allow the technology to be labelled ‘dermatologically tested’ for its cosmetic application.
Dr. Catherine O’Neill, CEO of SkinBioTherapeutics, said: “We are making progress in our research, and the extension and expansion of our contract with the University of Manchester will allow meaningful progression across the company. We are pleased with the progress of SkinBiotix, and are confident that it remains on track.”